In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Publication|Articles|September 9, 2024
Supplements and Featured Publications
- Prioritizing LDL-Cholesterol Control
Prioritizing LDL-Cholesterol Control
Listen
0:00 / 0:00
Key Takeaways
- LDL cholesterol management is vital for reducing cardiovascular disease risk and improving patient outcomes through effective lipid-lowering therapies.
- Advancements in therapies, such as PCSK9 inhibitors and statins, have significantly reduced LDL levels, enhancing cardiovascular health.
Advertisement
This supplement highlights the critical role of LDL cholesterol management in reducing cardiovascular disease and improving outcomes.
Advertisement
Related to this article
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A survivor shares axi-cel therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improves QOL.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
3
Access and Innovation in North Carolina’s Research Triangle
4
Baricitinib Approved for Severe Alopecia Areata in Adolescents
5